HC Q study #90
See all studies
Pre-Exposure Prophylaxis study (treated before exposed to the virus)
Ferri at al., Clinical Rheumatology, doi:0.1007/s10067-020-05334-7 (Peer Reviewed)
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
Analysis of 1641 systemic autoimmune disease patients showing csDMARD (HC Q etc.) RR 0.37, p=0.015.
csDMARDs include HC Q, C Q, and several other drugs, so the effect of HC Q/C Q alone could be higher.
This study also confirms that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, OR 4.42, p<0.001 (this is the observed real-world risk which takes into account factors such as these patients potentially being more careful to avoid exposure).
(reults are for "definite + highly suspected" cases and the main result is presented in the paper as the OR for not taking csDMARDs, we have converted this to RR for taking csDMARDs).
Source   Share   Tweet
See all studies
Please send us corrections, updates, or comments.